ClinicalTrials.gg

Program

eneboparatide

Also written as “AZP-3601”.

Its studies are mostly in Hypoparathyroidism, led by AstraZeneca.

Furthest: phase 3, since Mar 9, 20232 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca21 open or runningphase 3since Mar 9, 2023Jan 7, 2022none ahead
  • Named in AstraZeneca’s own pipeline as eneboparatide, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: amolyt-pharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 7, 2022First study: phase 2 study in Chronic HypoparathyroidismFirst studyNCT05239221 · 132 enrolled · Hungary, Netherlands
  2. Mar 9, 2023Phase 3 study in Endocrine System DiseasesNCT05778071 · 165 enrolled · United States, Canada, Denmark and more

TargetBeta

“A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)”study text, read by Claude · the study

Other programs on PTH1R

ProgramCompanyFurthest phaseStudies
Palopegteriparatideruleascendis-pharma-bone-diseases-a-sphase 35

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05778071Endocrine System Diseases · United States, Canada, Denmark and more3Active, not recruitingNov 15, 2024165
NCT05239221Chronic Hypoparathyroidism · Hungary, Netherlands2CompletedAug 23, 2022132

How it is read

Names in the registry

  • “eneboparatide”, 1 entry
  • “AZP-3601”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.